0.00Open0.05Pre Close0 Volume2.36K Open Interest2.00Strike Price0.00Turnover5744.88%IV22.75%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier-6DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.2553Delta0.8888Gamma33.40Leverage Ratio-11.7362Theta0.0000Rho8.53Eff Leverage0.0000Vega
Cerus Stock Discussion
Earnings Preview
Analysts estimate $Cerus (CERS.US)$ to post revenue of USD47.80M for 2024Q3, up 20.18% YOY;
EPS is estimated to be USD-0.03, Net Loss Narrowed 18.8% YoY.
The accounting standard used for the above data is US-GAAP.
Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe
Cerus (Nasdaq:CERS) has provided updates on its INTERCEPT red blood cell (RBC) programs in the U.S. and Europe. In the U.S., Cerus has secured a new $248 million contract with BARDA to support the program through FDA approval and commercialization. The company recently announced positive topline results for the ReCePI study, a pivotal U.S. Phase 3 clinical trial.
In Europe, the CE ...
Larger Image: tradingview.com...
$Cerus (CERS.US)$
Benzinga· 6 mins ago
Cerus Outlook FY Revenue USD 175-178 Million
No comment yet